Relapse-free survival of complete responders and competing risk of relapse and death in complete remission (CR). Control remission induction therapy versus clofarabine treatment. Relapse-free survival was assessed in patients following attainment of a CR/CRi (upper panel). Probabilities for the endpoint relapse (middle panel) and nonleukemic death (ie, death in continued CR) (lower panel) are also plotted for the comparative study arms.